Home Cart Sign in  
Chemical Structure| 1009817-63-3 Chemical Structure| 1009817-63-3

Structure of b-AP15
CAS No.: 1009817-63-3

Chemical Structure| 1009817-63-3

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

b-AP15 is an inhibitor of the ubiquitin carboxyl-terminal hydrolase isozyme L5 (UCHL5) and ubiquitin-specific-processing protease 14 (USP14). In purified 19S proteasomes, b-AP15 can inhibit DUB activity with an IC50 of 2.1 μM.

Synonyms: NSC 687852

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of b-AP15

CAS No. :1009817-63-3
Formula : C22H17N3O6
M.W : 419.39
SMILES Code : O=C1/C(CN(C(C=C)=O)C/C1=C\C2=CC=C([N+]([O-])=O)C=C2)=C/C3=CC=C([N+]([O-])=O)C=C3
Synonyms :
NSC 687852
MDL No. :MFCD26142662
InChI Key :GFARQYQBWJLZMW-JYFOCSDGSA-N
Pubchem ID :5351435

Safety of b-AP15

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P280-P305+P351+P338

Isoform Comparison

Biological Activity

Target
  • UCH

    UCHL5, IC50:2.1 μM

In Vitro:

Cell Line
Concentration Treated Time Description References
RT4 up to 2000 nM 24 hours Induced ER stress and apoptosis Mol Ther Oncolytics. 2022 Aug 5;26:387-398.
IMR-32 107.8 nM (IC50) 72 hours Inhibits cell proliferation and induces apoptosis Mol Cancer Ther. 2019 Jun;18(6):1045-1056.
LAN-6 127.8 nM (IC50) 72 hours Inhibits cell proliferation and induces apoptosis Mol Cancer Ther. 2019 Jun;18(6):1045-1056.
MelJuSo UbG76V-YFP cells 1 µM 1-3 hours To study the effect of b-AP15 on proteasome function, it was found that b-AP15 inhibited proteasome function and led to cell death. Antioxid Redox Signal. 2014 Dec 10;21(17):2271-85.
HeLa cells 10 µM 2 hours Immunoblot analysis showed that b-AP15 induced the formation of high molecular weight complexes with USP14. J Med Chem. 2020 Apr 9;63(7):3756-3762.
UMSCC1 cells 250 nM 24 hours B-AP15 significantly inhibited the growth and colony formation capacity of UMSCC1 cells. Cell Death Differ. 2023 May;30(5):1382-1396.
BFTC905 up to 2000 nM 24 hours Induced ER stress and apoptosis Mol Ther Oncolytics. 2022 Aug 5;26:387-398.
T24 up to 2000 nM 24 hours Induced ER stress and apoptosis Mol Ther Oncolytics. 2022 Aug 5;26:387-398.
T24/R up to 2000 nM 24 hours Induced ER stress and apoptosis Mol Ther Oncolytics. 2022 Aug 5;26:387-398.
Monocyte-derived dendritic cells 10 nM, 100 nM, 500 nM, 1000 nM 24 hours Comparative analysis of effects of bortezomib and b-AP15 on dendritic cell phenotype and function, finding that b-AP15 had no compromising effects on these DC features. Neoplasia. 2019 Jul;21(7):653-664.
MCF-7 0.5, 1, 2, 5 µM 24, 48, 72 hours To evaluate the effect of b-AP15 on the growth of ER+ breast cancer cells, results showed that b-AP15 significantly inhibited cell viability. Oncogenesis. 2018 Sep 24;7(9):75.
T47D 0.5, 1, 2, 5 µM 24, 48, 72 hours To evaluate the effect of b-AP15 on the growth of ER+ breast cancer cells, results showed that b-AP15 significantly inhibited cell viability. Oncogenesis. 2018 Sep 24;7(9):75.
PK-15 cells 0–1 µM 24–48 hours To evaluate the inhibitory effect of b-AP15 on PRV-GFP proliferation, results showed that b-AP15 significantly inhibited PRV-GFP proliferation. Autophagy. 2022 Aug;18(8):1801-1821.
3D4/21 cells 0–1 µM 24–48 hours To evaluate the inhibitory effect of b-AP15 on PRV-GFP proliferation, results showed that b-AP15 significantly inhibited PRV-GFP proliferation. Autophagy. 2022 Aug;18(8):1801-1821.
HNSCC cells 250 nM 48 hours B-AP15 significantly reduced the proliferation and survival of HNSCC cells and induced apoptosis. Cell Death Differ. 2023 May;30(5):1382-1396.
SU-DHL-4 0.205 µM 48 hours B-AP15 inhibited the proliferation and induced apoptosis in GCB-DLBCL cells. J Exp Clin Cancer Res. 2019 Nov 6;38(1):453.
SU-DHL-2 0.296 µM 48 hours B-AP15 inhibited the proliferation and induced apoptosis in ABC-DLBCL cells. J Exp Clin Cancer Res. 2019 Nov 6;38(1):453.
RKO 1-5 µM 48 hours B-AP15 significantly reduced the viability of RKO cells, with an IC50 value of 1.649 μM. Acta Pharmacol Sin. 2023 Dec;44(12):2537-2548.
RKO-R 1-5 µM 48 hours B-AP15 significantly reduced the viability of RKO-R cells, with an IC50 value of 0.987 μM. Acta Pharmacol Sin. 2023 Dec;44(12):2537-2548.
HCT-15 1-5 µM 48 hours B-AP15 significantly reduced the viability of HCT-15 cells, with an IC50 value of 1.453 μM. Acta Pharmacol Sin. 2023 Dec;44(12):2537-2548.
HCT-15R 1-5 µM 48 hours B-AP15 significantly reduced the viability of HCT-15R cells, with an IC50 value of 0.858 μM. Acta Pharmacol Sin. 2023 Dec;44(12):2537-2548.
HCT116 colon carcinoma cells 1 µM 6 hours To study the effect of b-AP15 on gene expression in HCT116 cells, it was found that b-AP15 induced the expression of genes related to oxidative stress, ER stress, and heat shock. Antioxid Redox Signal. 2014 Dec 10;21(17):2271-85.
KMBC cells 13 nM 72 hours Evaluate the sensitivity of b-AP15 in low BAP1 expressing cells, results showed increased sensitivity in KMBC cells with low BAP1 expression Mol Cancer. 2017 Jan 25;16(1):22.
HuCCT1 cells 1.9 µM 72 hours Evaluate the sensitivity of b-AP15 in high BAP1 expressing cells, results showed lower sensitivity in HuCCT1 cells with high BAP1 expression Mol Cancer. 2017 Jan 25;16(1):22.
HAP1 BAP1 KO cells 9 nM 72 hours Evaluate the sensitivity of b-AP15 in BAP1 knockout cells, results showed increased sensitivity in HAP1 BAP1 KO cells Mol Cancer. 2017 Jan 25;16(1):22.
HAP1 WT cells 38 nM 72 hours Evaluate the sensitivity of b-AP15 in wild-type cells, results showed lower sensitivity in HAP1 WT cells Mol Cancer. 2017 Jan 25;16(1):22.
HeLa cells 20 mM B-AP15 increased the levels of ubiquitinated proteins in cells and led to a 2- to 2.5-fold stimulation of proteasomal peptidase activity. Proc Natl Acad Sci U S A. 2022 Jun 21;119(25):e2122482119.
HCT116 colon cancer cells 1 µM Assess the cytotoxicity of b-AP15 on colon cancer cells J Med Chem. 2020 Dec 24;63(24):15075-15093.

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Nude mice Colon cancer xenograft model Intraperitoneal injection 100 mg/kg Daily Evaluate the antitumor activity of EF24 in colon cancer xenograft model J Med Chem. 2020 Dec 24;63(24):15075-15093.
Nude mice HNSCC tumor xenograft model Subcutaneous injection 5 mg/kg Multiple times per week for 2 weeks B-AP15 as a monotherapy or in combination with radiation significantly delayed tumor growth and enhanced survival. Cell Death Differ. 2023 May;30(5):1382-1396.
Nude mice NGP and SH-SY5Y xenograft models Intraperitoneal injection 5 mg/kg Once daily for two weeks Inhibits tumor growth and induces tumor cell apoptosis Mol Cancer Ther. 2019 Jun;18(6):1045-1056.
Nude mice SU-DHL-4 and SU-DHL-2 cell xenograft models Intraperitoneal injection 5 mg/kg/day Once daily for 11 days B-AP15 significantly inhibited the growth of GCB- and ABC-DLBCL xenograft models. J Exp Clin Cancer Res. 2019 Nov 6;38(1):453.
Nude mice CML xenograft model Intraperitoneal injection 5 mg/kg/day Once daily until the tumor volume reached 1500 mm³ B-AP15 significantly inhibited tumor growth in the CML xenograft model and reduced tumor volume and weight. Clin Transl Med. 2022 Sep;12(9):e1038
Mice Subcutaneous xenograft model Intraperitoneal injection 7.5 mg/kg Thrice a week for 4 weeks The combination of b-AP15 and cisplatin is superior to cisplatin monotherapy against UC in vivo Mol Ther Oncolytics. 2022 Aug 5;26:387-398.
Mice PRV infection model Intraperitoneal injection 8 mg/kg Every two days for 10 days To evaluate the protective effect of b-AP15 on PRV infection in vivo, results showed that b-AP15 significantly reduced the mortality of PRV-infected mice and inhibited PRV replication. Autophagy. 2022 Aug;18(8):1801-1821.
Nude mice RKO and RKO-R xenograft models Intraperitoneal injection 8 mg/kg/d Once daily, continuous treatment B-AP15 significantly suppressed the growth of RKO and RKO-R xenograft tumors without significantly affecting mouse body weight. Acta Pharmacol Sin. 2023 Dec;44(12):2537-2548.

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.38mL

0.48mL

0.24mL

11.92mL

2.38mL

1.19mL

23.84mL

4.77mL

2.38mL

References

 

Historical Records

Categories